Sign in
Taking people in NetherlandsPhase 3

Stopping Prostate Cancer Hormone Pill Drugs After One Year in Some Patients

Tests stopping androgen receptor drugs at 12 months in men with prostate cancer.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
's-Gravenhage, 'S-Gravenhage, Alkmaar, Almelo, Amersfoort, Amsterdam, Assen, Beverwijk, Deventer, Eindhoven, Emmen, Enschede, Goes, Groningen, Haarlem, Hilversum, Leeuwarden, Maastricht, Nieuwegein, Nijmegen, Roermond, Roosendaal, Rotterdam, and Venlo, NetherlandsSee the 28 sites
Registry title
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study
Status
Recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
2 Feb 2024
Expected to end
1 Sept 2031
Type of study
Interventional
Record updated
3 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread a little (low-volume) and still responds to hormone therapy. It tests stopping the extra drug after 12 months.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma with low-volume metastatic disease (M1a or M1b) found at diagnosis, confirmed by bone scan and CT or by PSMA-PET scan. Performance status ECOG 0, 1 or 2.
Earlier treatment
Hormone therapy (ADT) started within 6 weeks before joining. No other prior treatment for prostate cancer, such as other anti-androgens, CYP17 inhibitors, chemotherapy, immunotherapy or radiopharmaceutical agents.

Main reasons for not taking part

  • Small cell, ductal or neuroendocrine prostate cancer
  • Another cancer within 5 years, except squamous or basal cell skin cancer or non-invasive superficial bladder cancer
  • History of seizures or medicines that lower the seizure threshold
  • Any prostate cancer treatment other than ADT
  • ADT started more than 6 weeks before joining

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male and ≥18 years of age
  • Histological diagnosis of prostate adenocarcinoma
  • Low-volume de novo metastatic disease (M1a or M1b) defined as anything other than fitting the criteria for high-volume metastatic disease, e.g., four or more bone lesions with one or more lesions in any body structure beyond the spine or pelvis, or visceral disease (non-nodal). This has been assessed by either bone scan and computed tomography (CT), or PSMA-PET scan. Low-volume disease has subsequently been confirmed by the local (multidisciplinary) team after consideration of the available imaging results as per the standard imaging protocol for the site
  • ADT initiated within 6 weeks prior to inclusion
  • Eastern Cooperative Oncology Group (ECOG) performance scale status of 0, 1 or 2
  • Fit for treatment with apalutamide or enzalutamide according to treating physician
  • Capable of understanding and complying with protocol requirements and able to understand and sign the informed consent form

Who cannot take part

  • Any other prior treatment for prostate cancer other than ADT (e.g., other next generation anti-androgens or other CYP17 inhibitors, chemotherapy, immunotherapy, or radiopharmaceutical agents)
  • ADT started more than 6 weeks before inclusion
  • Other prior malignancy less than or equal to 5 years prior to randomization except for squamous or basal cell skin carcinoma or non-invasive superficial bladder cancer
  • History of seizures or medications known to lower seizure threshold
  • Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate

Where in Netherlands

  • Haga Hospital's-Gravenhage, NetherlandsTaking people
  • Haaglanden Medisch Centrum Stichting'S-Gravenhage, NetherlandsTaking people
  • Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
  • Ziekenhuisgroep Twente StichtingAlmelo, NetherlandsTaking people
  • Meander Medisch CentrumAmersfoort, NetherlandsTaking people
  • Amsterdam UMCAmsterdam, NetherlandsTaking people
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
  • Wilhelmina Ziekenhuis AssenAssen, NetherlandsTaking people
  • Rode Kruis Ziekenhuis B.V.Beverwijk, NetherlandsTaking people
  • Deventer ZiekenhuisDeventer, NetherlandsTaking people
  • Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
  • Stichting Treant ZiekenhuiszorgEmmen, NetherlandsTaking people
  • Medisch Spectrum TwenteEnschede, NetherlandsTaking people
  • ADRZGoes, NetherlandsTaking people
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
  • Spaarne Gasthuis StichtingHaarlem, NetherlandsTaking people
  • TergooiziekenhuizenHilversum, NetherlandsTaking people
  • Medisch Centrum Leeuwarden B.V.Leeuwarden, NetherlandsTaking people
  • Universiteit MaastrichtMaastricht, NetherlandsTaking people
  • Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
  • Canisius-Wilhelmina HospitalNijmegen, NetherlandsTaking people
  • Laurentius Ziekenhuis RoermondRoermond, NetherlandsTaking people
  • Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
  • Ikazia ZiekenhuisRotterdam, NetherlandsTaking people
  • Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
  • Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
  • Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people

About the trial

What the trial wants to find out

To evaluate whether the discontinuation of ARSIs 12 months after its initiation in low-volume metastatic castration-sensitive prostate cancer (mCSPC) patients with the possibility to restart treatment, is non-inferior to continued androgen receptor signaling inhibitors (ARSI), thereby sparing significant toxicity and costs

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial
Plain-language title
Stopping Prostate Cancer Hormone Pill Drugs After One Year in Some PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 December 2025